Core Insights - Therma Bright Inc. has received a follow-on order for 200 additional Venowave™ VW5 units from Gen-X Med, indicating strong clinical demand for the product [1][2][3] Company Overview - Therma Bright Inc. specializes in advanced diagnostic and medical device technologies, focusing on innovative solutions for vascular health, respiratory diagnostics, and topical treatments [6] - The company is publicly traded on the TSX Venture Exchange (THRM), OTCQB (TBRIF), and Frankfurt Stock Exchange (JNX0) [6] Product Details - The Venowave™ VW5 is a portable, battery-operated device designed for at-home treatment of circulatory disorders, enhancing venous blood flow by 64% after two minutes and 88% after 50 minutes of use [5] - It is the only Medicare-approved reimbursable mobile mechanical compression system in the U.S. under HCPCS code E0683, providing a comfortable solution for post-operative recovery [5] Market Insights - The global compression therapy market was valued at $4.18 billion in 2024 and is projected to reach $6.72 billion by 2033, growing at a CAGR of 7.30% [4] - Growth is driven by an aging population, increased orthopedic surgeries, and a focus on preventing Deep Vein Thrombosis (DVT) and other circulatory disorders [4] Partnership Development - The order from Gen-X Med signifies an expansion of the relationship between Therma Bright and Gen-X Med, following the successful integration of the Venowave™ system into Gen-X Med's healthcare network [2][3] - Gen-X Med's President noted a shift towards at-home recovery solutions, with Venowave™ leading this transition [4]

Core Insights - Therma Bright Inc. has expanded its partnership with Gen-X Med to enhance the distribution of its Venowave™ VW5 units, targeting specialized knee surgeons in the U.S. healthcare network [1][2] - The initial sale of 200 units has shown positive patient outcomes, leading to expectations for additional orders as awareness of the product increases [2] - The Venowave™ VW5 is positioned as a significant innovation in the compression therapy market, which is projected to grow from $4.18 billion in 2024 to $6.72 billion by 2033, reflecting a CAGR of 7.30% [2] Company Overview - Therma Bright Inc. specializes in advanced diagnostic and medical device technologies, focusing on solutions that improve patient outcomes and reduce healthcare costs [1][5] - The Venowave™ VW5 is a portable device designed to treat circulatory disorders, enhancing venous blood flow significantly and approved for Medicare reimbursement [3] Industry Context - The global compression therapy market is experiencing robust growth, indicating a rising demand for innovative medical solutions like the Venowave™ VW5 [2] - The partnership with Gen-X Med is a strategic move to penetrate a high-value segment of the U.S. healthcare market, particularly in post-surgical recovery [2][4]